NGLFINE2,701.00

NGL Fine-Chem Limited

· Pharma & Health
₹ CrorePeersSYNCOMFJAGSNPHARMHESTERBIOAMRUTANJANWINDLASINDOCOSAIPARENTMcap ₹1,669 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation11.612.519.6
+ Finance Costs0.02.34.5
+ Interest Income0.0-0.6-0.7
+ Dividend Income0.0-0.2-0.0
+ Other Non-cash Items-0.2-0.2-0.2
+ Other Reconciling Items0.00.02.7
Changes in Working Capital
+ Inventories-16.3-8.0-19.0
+ Trade Receivables — Current-23.78.1-48.0
+ Other Financial Assets — Current-11.4-12.33.9
+ Other Financial Assets — Non-current-0.17.80.0
+ Other Current Assets-6.0-10.42.4
+ Other Non-current Assets-1.5-1.71.1
+ Trade Payables — Current24.88.112.5
+ Other Financial Liabilities — Current0.38.217.4
+ Other Financial Liabilities — Non-current1.30.01.5
+ Other Current Liabilities-0.2-0.7-2.4
+ Other Non-current Liabilities0.90.3-0.8
+ Provisions — Current0.10.70.1
+ Provisions — Non-current0.50.80.7
Cash from Operating Activities
Profit Before Tax (per I/S)54.427.763.475.9
+ Total Adjustments (incl. Working Capital)-19.814.7-4.8
Cash from Operations (pre-tax)34.642.458.6
+ Interest Received — Operating-0.60.00.0
+ Dividends Received — Operating-0.50.00.0
+ Income Taxes Paid13.16.615.2
Cash from Operating Activities20.535.843.3
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)28.5130.889.9
+ Disp of Fixed Assets0.057.03.8
+ Disp of Investment Property0.00.020.5
+ Receipts on Futures / Forwards / Options / Swaps0.00.0-2.7
+ Dividends Received — Investing0.50.20.0
+ Interest Received — Investing0.60.60.7
+ Other Inflows / (Outflows) — Investing0.638.4-3.0
Cash from Investing Activities-26.8-34.6-70.6
Cash from Financing Activities
+ Proceeds from Borrowings0.00.035.1
+ Interest Paid0.00.04.5
+ Dividends Paid1.11.11.1
+ Other Inflows / (Outflows) — Financing-0.00.00.0
Cash from Financing Activities-1.1-1.129.5
Net Changes in Cash (pre-FX)-7.40.22.3
+ Effect of FX Rate Changes on Cash0.00.00.5
Net Changes in Cash-7.40.22.8
Closing Cash0.4
Reference Items
EBITDA53.333.972.784.2
EBITDA Margin %15.739.2014.5115.70
Free Cash Flow (CFO − Capex)-8.1-94.9-46.5-46.5
Free Cash Flow to Equity-54.2-15.7
Free Cash Flow per Basic Share-13.04-153.69-75.32-75.32
Cash Flow to Net Income0.501.700.90
Cash Paid for Taxes13.16.615.2
Cash Paid for Interest0.00.04.5
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.